Clinical Research Directory

Inclusion Criteria: * To be eligible for participation in this study, subjects must meet the following inclusion criteria: 1. Patients who have been administered Dovprela Tablets according to the current local labelling after the study is initiated at the study institution 2. Subjects who have consented to participate in this study by signing the data privacy statement Exclusion Criteria: * Patients falling under any of the following criteria are not included in the study: 1. Cases with duplicated studies (In the event of duplicated cases, the case that has been collected first will be recognized.) 2. Patients with hypersensitivity to active substance (Pretomanid) or components. The list of components is as follows: \*Components: Lactose monohydrate, microcrystalline cellulose, povidone, sodium starch glycolate, magnesium stearate, colloidal silicon dioxide, sodium lauryl sulfate 3. Patients with contraindications to use Bedaquiline and/or Linezolid as Dovprela Tablets are used as a combination treatment with Bedaquiline and Linezolid 4. Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption 5. Other patients whom the investigator decides not to prescribe under general practice, considering the overall balance of risks and benefits, such as those who are pregnant or breastfeeding If data of the subjects that have not been used within the scope of permitted items is collected, it shall be analysed as a separate item.